» Articles » PMID: 33288545

SLAMF7 Signaling Reprograms T Cells Toward Exhaustion in the Tumor Microenvironment

Overview
Journal J Immunol
Date 2020 Dec 8
PMID 33288545
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

T cell exhaustion represents one of the most pervasive strategies tumors employ to circumvent the immune system. Although repetitive, cognate TCR signaling is recognized as the primary driving force behind this phenomenon, and it remains unknown what other forces drive T cell exhaustion in the tumor microenvironment (TME). In this study, we show that activation of the self-ligand SLAMF7 immune receptor on T cells induced STAT1 and STAT3 phosphorylation, expression of multiple inhibitory receptors, and transcription factors associated with T cell exhaustion. Analysis of The Cancer Genome Atlas revealed that SLAMF7 transcript levels were strongly correlated with various inhibitory receptors and that high SLAMF7 expression was indicative of poor survival in clear cell renal cell carcinoma (ccRCC). Targeted reanalysis of a CyTOF dataset, which profiled the TME in 73 ccRCC patients, revealed cell-type-specific SLAMF7 expression patterns, strong correlations between exhausted T cells and SLAMF7 tumor-associated macrophages (TAMs), and a unique subset of SLAMF7CD38 TAMs. These SLAMF7CD38 TAMs showed the strongest correlations with exhausted T cells and were an independent prognostic factor in ccRCC. Confirmatory ex vivo coculture studies validated that SLAMF7-SLAMF7 interactions between murine TAMs and CD8 T cells induce expression of multiple inhibitory receptors. Finally, mice lacking SLAMF7 show restricted growth of B16-F10 tumors, and CD8 T cells from these mice express less PD-1 and TOX and exhibited an impaired ability to progress through the exhaustion developmental trajectory to terminal exhaustion. These findings suggest that SLAMF7 might play an important role in modulating T cell function in the TME.

Citing Articles

Myeloid cells meet CD8 T cell exhaustion in cancer: What, why and how.

Zhai Y, Liang X, Deng M Chin J Cancer Res. 2025; 36(6):616-651.

PMID: 39802897 PMC: 11724180. DOI: 10.21147/j.issn.1000-9604.2024.06.04.


Single-Cell Transcriptome Reveals the Heterogeneity of T Cells in Mice with Systemic Lupus Erythematosus and Neuronal Inflammation.

Shi Z, Qin H, Wu H J Inflamm Res. 2024; 17:11375-11402.

PMID: 39735894 PMC: 11675326. DOI: 10.2147/JIR.S474211.


SLAMF7 defines subsets of human effector CD8 T cells.

Kared H, Tan C, Narang V, Tan S, Xian C, Wei A Sci Rep. 2024; 14(1):30779.

PMID: 39730488 PMC: 11680708. DOI: 10.1038/s41598-024-80971-5.


Multiomic profiling of chronically activated CD4+ T cells identifies drivers of exhaustion and metabolic reprogramming.

Lawton M, Inge M, Blum B, Smith-Mahoney E, Bolzan D, Lin W PLoS Biol. 2024; 22(12):e3002943.

PMID: 39689157 PMC: 11703073. DOI: 10.1371/journal.pbio.3002943.


Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics.

Shi Y, Zhao W, Ding Y, Ge X, Ju M Front Immunol. 2024; 15:1467098.

PMID: 39687627 PMC: 11647020. DOI: 10.3389/fimmu.2024.1467098.


References
1.
Soldatos T, Dimitrakopoulou-Strauss A, Larribere L, Hassel J, Sachpekidis C . Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. Diagnostics (Basel). 2018; 8(4). PMC: 6316083. DOI: 10.3390/diagnostics8040076. View

2.
Dongre P, Mathew S, Akopova I, Gryczynski I, Mathew P . YY1 and a unique DNA repeat element regulates the transcription of mouse CS1 (CD319, SLAMF7) gene. Mol Immunol. 2013; 54(3-4):254-63. DOI: 10.1016/j.molimm.2012.12.017. View

3.
Andrews L, Yano H, Vignali D . Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019; 20(11):1425-1434. DOI: 10.1038/s41590-019-0512-0. View

4.
Yigit B, Wang N, Ten Hacken E, Chen S, Bhan A, Suarez-Fueyo A . SLAMF6 as a Regulator of Exhausted CD8 T Cells in Cancer. Cancer Immunol Res. 2019; 7(9):1485-1496. DOI: 10.1158/2326-6066.CIR-18-0664. View

5.
Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View